The antibody drug conjugates market is estimated to be worth USD 23.3 billion in 2035, predicts Roots Analysis

Driven by the success of 14 approved antibody drug conjugates (ADCs) and a promising development pipeline, the field of antibody drug conjugates has gained significant traction in the last few years. Roots Analysis is pleased to announce the publication of its recent study, titled, "Antibody Drug Conjugates Market (7th Edition) Market

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-quote.html

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:
1. A detailed assessment of the market landscape of close to 400 antibody drug conjugates / ADC therapeutics that are either approved or being evaluated in different stages of development
2. An insightful competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
3. Elaborate profiles of leading antibody drug conjugate companies (shortlisted based on sales revenue of 2022) and their respective product portfolios.
4. An in-depth analysis of completed, ongoing, and planned clinical studies of various antibody drug conjugates
5. An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibody drug conjugates
6. An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates.
7. A detailed analysis of partnerships established by stakeholders engaged in this industry, since 2014
8. An analysis of the various funding and investments made in the ADC domain, in the recent past
9. An in-depth analysis of the various patents that have been filed / granted related to antibody drug conjugates
10. A study of the various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016
11. An elaborate discussion on commercialization strategies adopted by various drug developers for their respective products
12. An analysis of the key promotional strategies that have been adopted by the developers of marketed products
13. An insightful success protocol analysis of recently approved ADC therapeutics, based on several relevant parameters
14. An overview on of various conjugation and linker technologies along with their types that are presently being employed in the designing and development of antibody drug conjugates
15. An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in antibody drug conjugates
16. An elaborate discussion on various factors that form the basis for the pricing of antibody drug conjugate products
17. A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
18. A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates
19. A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution
20. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Target Disease Indication
1. Acute Lymphoblastic Leukemia
2. Breast Cancer
3. B-Cell Lymphoma
4. Cervical Cancer
5. Gastric Cancer
6. Lung Cancer
7. Multiple Myeloma
8. Renal Cancer
9. Other Target Disease Indications

Therapeutic Area
1. Hematological Cancer
2. Solid Tumor

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-sample.html

Linker
1. Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
2. Maleimide
3. Maleimidocaproyl
4. Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
5. Tetrapeptide-Based Linker
6. Valine-Alanine
7. Valine-Citrulline
8. Other Linkers

Payload
1. DM1
2. DM4
3. Duocarmycin
4. Monomethyl auristatin E (MMAE)
5. Monomethyl auristatin F (MMAF)
6. Ozogamicin
7. SG3199
8. SN-38 / Irinotecan
9. Other Payloads

Target Antigen
1. BCMA (TNFRSF17 / BCM)
2. CD19
3. CD22
4. CD30
5. CD79b
6. CEACAM5
7. HER-2 (ERBB2)
8. Nectin 4
9. Tissue factor
10. TROP-2
11. Other Target Antigen

Key Geographical Regions
1. North America
2. Europe
3. Asia-Pacific and Rest of the World

Key companies covered in the report

1. ADC Therapeutics
2. Astellas Pharma
3. AstraZeneca
4. Byondis
5. Daiichi Sankyo
6. Genentech
7. Gilead Sciences
8. ImmunoGen
9. Pfizer
10. RemeGen

Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.